BioSpecifics Technologies Corp (NASDAQ:BSTC) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokerages have set a one year consensus target price of $65.00 for the company and are forecasting that the company will post $0.39 EPS for the current quarter, according to Zacks. Zacks has also given BioSpecifics Technologies an industry rank of 113 out of 265 based on the ratings given to related companies.
Several equities analysts have recently issued reports on BSTC shares. Zacks Investment Research raised BioSpecifics Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. HC Wainwright restated a “buy” rating and set a $65.00 price target (down from $72.00) on shares of BioSpecifics Technologies in a research report on Monday, November 13th. Finally, dropped their price target on BioSpecifics Technologies from $72.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 15th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC boosted its position in shares of BioSpecifics Technologies by 253.0% during the third quarter. Stonepine Capital Management LLC now owns 211,370 shares of the biopharmaceutical company’s stock valued at $9,833,000 after purchasing an additional 151,492 shares in the last quarter. Elk Creek Partners LLC boosted its position in shares of BioSpecifics Technologies by 17.0% during the third quarter. Elk Creek Partners LLC now owns 170,102 shares of the biopharmaceutical company’s stock valued at $7,913,000 after purchasing an additional 24,696 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of BioSpecifics Technologies by 1.5% during the third quarter. Dimensional Fund Advisors LP now owns 269,554 shares of the biopharmaceutical company’s stock valued at $12,540,000 after purchasing an additional 3,878 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of BioSpecifics Technologies by 9.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 41,812 shares of the biopharmaceutical company’s stock valued at $1,946,000 after purchasing an additional 3,541 shares in the last quarter. Finally, Cadence Capital Management LLC boosted its position in shares of BioSpecifics Technologies by 5.1% during the third quarter. Cadence Capital Management LLC now owns 29,586 shares of the biopharmaceutical company’s stock valued at $1,376,000 after purchasing an additional 1,433 shares in the last quarter. Institutional investors own 55.93% of the company’s stock.
BioSpecifics Technologies (NASDAQ:BSTC) traded up $0.08 on Friday, hitting $43.33. The stock had a trading volume of 21,936 shares, compared to its average volume of 19,546. BioSpecifics Technologies has a 52-week low of $41.95 and a 52-week high of $58.79. The stock has a market capitalization of $310.93, a PE ratio of 27.25 and a beta of 1.58.
BioSpecifics Technologies (NASDAQ:BSTC) last posted its earnings results on Friday, November 10th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.01. BioSpecifics Technologies had a return on equity of 19.11% and a net margin of 42.40%. The firm had revenue of $6.52 million for the quarter, compared to analysts’ expectations of $6.59 million. equities analysts anticipate that BioSpecifics Technologies will post 1.57 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/14/biospecifics-technologies-corp-bstc-given-65-00-average-target-price-by-brokerages.html.
BioSpecifics Technologies Company Profile
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Get a free copy of the Zacks research report on BioSpecifics Technologies (BSTC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.